A 58-year-old man from Bangalore presents with a 3-month history of a rapidly enlarging, hard, fixed thyroid mass with dysphagia and stridor. On examination, the thyroid is grossly enlarged with a stony-hard consistency. Serum TSH is normal. FNAC shows numerous mitotic figures, marked cellular pleomorphism, and necrosis. The cells are large, polygonal, and spindle-shaped with high nuclear-to-cytoplasmic ratio. What is the most likely diagnosis?

Explanation

## Diagnosis: Anaplastic Carcinoma of Thyroid ### Clinical Presentation The patient presents with **rapid growth** (3 months), **stridor and dysphagia** (airway/esophageal compression), and a **stony-hard, fixed mass**—classic for anaplastic carcinoma (ATC), the most aggressive thyroid malignancy. **Key Point:** Anaplastic carcinoma is the most rapidly progressive thyroid cancer and is almost always fatal within 1 year without multimodal therapy. ### Cytopathological Features The FNAC findings are diagnostic: - **Marked cellular pleomorphism** — extreme variation in cell size and shape - **High mitotic rate** — numerous mitotic figures - **Tumor necrosis** — areas of cell death - **Large, polygonal and spindle cells** — loss of differentiation - **High nuclear-to-cytoplasmic ratio** — reflects aggressive biology ### Epidemiology & Risk Factors | Feature | Detail | |---------|--------| | Age | Typically >60 years (this patient is 58, still typical) | | Gender | Slight female predominance | | Prior history | Often arises from pre-existing differentiated thyroid cancer (PTC or FTC) | | Incidence | 1–2% of all thyroid cancers but accounts for ~50% of thyroid cancer deaths | **High-Yield:** ATC is often a **dedifferentiated form** of papillary or follicular carcinoma; always ask about prior thyroid disease. ### Pathological Classification **Key Point:** Anaplastic carcinoma is classified as an **undifferentiated thyroid carcinoma** and has **lost the ability to concentrate iodine**, making radioactive iodine therapy ineffective. ### Molecular Pathology Common mutations in ATC: - **TP53** (loss of function) — most frequent - **BRAF V600E** — present in ~25% (especially if arising from PTC) - **RAS mutations** — common - **PTEN loss** — promotes aggressive phenotype ### Staging & Prognosis **Mnemonic:** ATC is **TNM Stage IVA/IVB/IVC** (all ATC are Stage IV by definition): - **IVA:** Intrathyroidal disease (still surgically resectable) - **IVB:** Gross extrathyroidal extension - **IVC:** Distant metastases (lungs, bone, brain) **Clinical Pearl:** Median survival is **3–6 months** without treatment; with aggressive multimodal therapy (surgery + chemotherapy + radiation), median survival extends to ~12–18 months. ### Management Algorithm ```mermaid flowchart TD A[Anaplastic Carcinoma Diagnosed]:::outcome --> B{Resectable?}:::decision B -->|Yes| C[Total thyroidectomy + central/lateral neck dissection]:::action B -->|No| D[Neoadjuvant chemotherapy + radiation]:::action C --> E[Adjuvant chemotherapy + external beam radiation]:::action D --> F[Reassess resectability]:::decision F -->|Yes| G[Debulking surgery]:::action F -->|No| H[Palliative chemotherapy + supportive care]:::action E --> I[Molecular testing for targeted therapy]:::action G --> I I --> J[Consider BRAF inhibitors if BRAF V600E positive]:::action ``` ### Differential Features from Other Thyroid Malignancies | Feature | ATC | PTC | FTC | MTC | |---------|-----|-----|-----|-----| | Growth rate | Rapid (weeks–months) | Slow (months–years) | Intermediate | Intermediate | | Cytology | Pleomorphic, high mitosis | Papillary, grooves | Follicular, microfollicles | Spindle/polygonal | | RAI uptake | No | Yes | Yes | No | | Prognosis | Dismal (3–6 mo) | Excellent (90% 10-yr) | Good (85% 10-yr) | Intermediate (50–80%) | | TNM Stage | All Stage IV | I–IV | I–IV | I–IV |